US paediatric panel to review adverse events for 11 drugs
This article was originally published in Scrip
The US FDA's paediatric advisory panel will meet on November 18th to review adverse event reports for 11 drugs under the Best Pharmaceuticals for Children Act. The medicines areAlcon's Betoptic S (betaxolol), Graceway Pharmaceuticals' Aldara (imiquimod),GlaxoSmithKline's Lamictal (lamotrigine),Johnson & Johnson's Levaquin (levofloxacin),Novartis's Sandostatin (octreotide),Lilly's Zyprexa (olanzapine), J&J's Risperdal (risperidone), Novartis's Lamisil (terbinafine), Falcon Pharmaceuticals' Timolol GFS (timolol) andSanofi-Aventis's Ambien (zolpidem). The panel also will be given a written follow-up report onPfizer's Zyvox (linezolid), as requested at a November 2006 meeting.
You may also be interested in...
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
Agency is working with manufacturers, including Takeda and Emergent BioSolutions, to accelerate development of hyperimmune globulin products, with an eye toward starting clinical testing in several months; new FDA guidelines on convalescent plasma collection for single-patient emergency IND use are helpful in understanding agency expectations around source plasma collection for manufactured products as well, Emergent SVP Laura Saward says.